NCT06876623View on ClinicalTrials.gov

Bioequivalence Study of Two Dabigatran Etexilate Mesylate Capsules in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

December 10, 2019

Primary Completion Date

June 12, 2020

Study Completion Date

June 12, 2020

Conditions
Bioequivalence of Dabigatran Etexilate Mesylate Capsules From Two Different Manufacturers in Healthy Chinese Subjects
Interventions
DRUG

dabigatran etexilate mesylate capsules 150mg

Oral dabigatran etexilate mesylate capsules，150mg Once every seven days，two cycle T drug, two cycles R drug

Trial Locations (1)

Unknown

Clinical Trials Center, The Affiliated Hospital of Guizhou Medical University, Guiyang

All Listed Sponsors
lead

The Affiliated Hospital Of Guizhou Medical University

OTHER

NCT06876623 - Bioequivalence Study of Two Dabigatran Etexilate Mesylate Capsules in Healthy Subjects | Biotech Hunter | Biotech Hunter